As cell therapy programs advance toward pivotal trials and commercialization, manufacturing processes, analytical methods, and quality systems must mature to meet rising regulatory expectations. Kincell Bio supports late-phase development by strengthening process control, expanding analytical rigor, and delivering reliable GMP manufacturing, generating the data, documentation, and consistency required to support regulatory filings and long-term commercial success.
While autologous therapies comprise the majority of today’s commercial cell therapies, ongoing innovation is accelerating the shift toward scalable, “off-the-shelf” allogeneic solutions. Kincell Bio collaborates with innovators and enabling technology providers to support ever-expanding cell therapy approaches.
Kincell Bio specializes in autologous cell therapy manufacturing with rapid turnaround, strict chain-of-custody, and patient-focused quality systems.
We support scalable allogeneic cell therapy manufacturing with robust process control, analytics, and commercial readiness.
Kincell’s late-phase CMC capabilities strengthen process definition, analytical control strategies, and regulatory documentation to support pivotal trials and commercialization. Integrated process development, analytics, and GMP manufacturing generate the data and control required for IND amendments, comparability planning, and BLA readiness.
Kincell provides GMP manufacturing services across the full cell therapy lifecycle, with our Gainesville, FL, USA facility focused on early CMC and clinical supply, and our Research Triangle Park, NC, USA facility emphasizing pivotal and commercial manufacturing. Together, the two facilities provide scalable and redundant GMP capacity, robust analytics, and expansion-ready infrastructure to ensure long-term program continuity and supply reliability.
In our new eBook, Navigating Intensifying Cell Therapy Regulatory Expectations, Kincell Bio’s scientific and executive leadership break down what’s changed, why programs...
This webinar explores how integrated PD/AD expertise can deliver robust, regulatory-ready assays and accelerates cell therapy development.
An inside look at how our CMC expertise, advanced process development, and proven manufacturing operations help innovators accelerate their IND, strengthen late-stage...
Talk to an expert
Leveraging our science-first expertise and right-first-time quality, partner with Kincell Bio to advance your cell therapy from concept to commercialization.
"*" indicates required fields
